Join
Live feed
·
INSIDERFilingvia Quantisnow
Allogene Therapeutics Inc. logo

Director Kazam Joshua A converted options into 47,700 shares, increasing direct ownership by 16% to 350,763 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ALLO· Allogene Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLO (Allogene Therapeutics Inc.) and more on Quantisnow.